基于MRI的瘤内异质性定量预测阿替利珠单抗-贝伐珠单抗联合TACE/HAIC治疗肝细胞癌的疗效
该多中心研究纳入151例不可切除肝细胞癌患者,从MRI提取常规和habitat影像组学特征构建瘤内异质性(ITH)评分,并联合临床变量和影像组学特征建立联合模型。联合模型预测三重治疗疗效的AUC在训练、验证和测试队列分别为0.971、0.937和0.868,并能对无进展生存期和总生存期进行风险分层。
要点
- 基于MRI的ITH评分联合临床和影像组学特征可预测阿替利珠单抗-贝伐珠单抗联合TACE/HAIC的疗效。
- 联合模型预测治疗反应的AUC在训练、验证和测试队列分别为0.971、0.937和0.868。
- 联合模型可将患者分为无进展生存期和总生存期的高危和低危组。
核心结论
- 基于MRI的ITH评分联合临床和影像组学特征,为接受阿替利珠单抗-贝伐珠单抗联合TACE/HAIC治疗的肝细胞癌患者提供了稳健的治疗反应预测工具。
研究设计与样本
- 多中心研究,纳入2019年1月至2024年1月期间接受阿替利珠单抗-贝伐珠单抗联合TACE/HAIC治疗的不可切除肝细胞癌患者151例,从MRI提取常规和habitat影像组学特征构建ITH评分,并建立基于临床变量、影像组学特征和ITH评分的预测模型。
诊断标准与关键数值
- 88例患者(58.3%)对阿替利珠单抗-贝伐珠单抗联合TACE/HAIC治疗有反应。
- 联合模型整合临床变量、影像组学特征和ITH评分,预测三重治疗疗效的AUC在训练队列为0.971、验证队列为0.937、测试队列为0.868。
- 联合模型可将患者分为无进展生存期和总生存期的高危和低危组,训练队列p < 0.001(PFS和OS)、验证队列p < 0.001(PFS和OS)、测试队列p = 0.005(PFS)和p < 0.001(OS)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Hepatocellular carcinoma (HCC) is highly heterogeneous, resulting in different treatment responses to anti-tumor therapy. The present study aimed to investigate the prognostic value of noninvasive MRI-based intratumoral heterogeneity (ITH) quantification for predicting treatment response to atezolizumab-bevacizumab combined with transarterial chemoembolization (TACE) /hepatic artery infusion chemotherapy (HAIC) in unresectable HCC.
MATERIALS AND METHODS: Patients with unresectable HCC (n=151) who received atezolizumab-bevacizumab combined with TACE/HAIC at multiple centers were enrolled between January 2019 and January 2024. Conventional and habitat radiomic features were extracted from MRI to construct the ITH score. Predictive models based on clinical variables, radiomic features, and the ITH score were developed and evaluated using the area under the receiver operating characteristic curve (AUC).
RESULTS: 88 patients (58.3%) showed a response to atezolizumab-bevacizumab combined with TACE/HAIC. The combined model integrating clinical variables, radiomic features, and the ITH score achieved the highest accuracy in predicting treatment response to triple therapy with an AUC of 0.971, 0.937, and 0.868 in the training, validation, and testing cohort, respectively. Furthermore, the combined model can categorize patients into high-risk and low-risk groups for progression-free survival (PFS) and overall survival (OS) in the training (p < 0.001 for PFS and OS), validation (p < 0.001 for PFS and OS) and testing cohort (p = 0.005 for PFS; p < 0.001 for OS).
CONCLUSION: The MRI-based ITH score, when combined with clinical and radiomic features, provides a robust predictive tool for treatment response in HCC patients undergoing atezolizumab-bevacizumab combined with TACE/HAIC.
DATA AVAILABILITY STATEMENT: The datasets generated or analyzed during the study are available from the corresponding author on reasonable request.
引用
- Yan HT, Zu QQ, Hua HJ, et al. MRI-Based Quantification of Intratumoral Heterogeneity Predicts Response in Hepatocellular Carcinoma Treated with Atezolizumab-Bevacizumab and TACE/HAIC. Acad Radiol. 2025. PMID: 40617706. doi:10.1016/j.acra.2025.06.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。